Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

71.46EUR
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
€71.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,981
52-wk High
€76.36
52-wk Low
€59.00

Select another date:

Wed, Jan 18 2017

BRIEF-Colucid Pharmaceuticals says termination fee of $34 mln to be payable to Eli Lilly upon termination

* Colucid Pharmaceuticals - upon termination of deal under specified circumstances, co will be required to pay Eli Lilly termination fee of $34 million Source text (http://bit.ly/2jKbOWp) Further company coverage:

BRIEF-U.S. appeals court rejects Teva appeal in Lilly patent case over Alimta

Jan 12 U.S. Appeals Court rules for Eli Lilly and against Teva Pharmaceutical in Alimta patent case -- court ruling

US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday

* Dow up 0.1 pct, S&P down 0.1 pct, Nasdaq down 0.3 pct (Updates to late afternoon, adds dateline)

BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

* Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3

* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly and Co says new data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes

* New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.51/share

* Sets quarterly dividend of $0.51 per share Source text for Eikon: Further company coverage:

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

BRIEF-EMA recommends approval of three new cancer treatments

* Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes

BRIEF-Levi Garraway to become senior vice president of global oncology at Lilly

* Levi garraway, m.d., ph.d., to become senior vice president of global oncology at lilly, succeeding richard gaynor, m.d., who is retiring after a distinguished career

Select another date: